| Authors: |
Opdam M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ultee N; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Geenen JJJ; Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rossum AGJ; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Data Center, Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Biometrics Division, Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wesseling J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Menezes RX; Biostatistics Centre, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Oosterkamp HM; Department of Medical Oncology, Haaglanden Medisch Centrum, The Hague, the Netherlands., Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands. Electronic address: s.linn@nki.nl. |